Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇸🇬SG · Life Sciences#1003K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1.5K to 5K🎙 ~2x weekly·14 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
3K to 10K🇸🇬100% - Active Followers
Loyal subscribers who consistently listen
1.2K to 4K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Dr. Rich Miller: “There Are No Biomarkers of Aging”
Jun 29, 2026
Unknown duration
GLP-1 Agonists and Longevity: The First ReProgram Scorecard
Jun 15, 2026
Unknown duration
Can AI Decode Human Aging?
Jun 1, 2026
Unknown duration
NAD and Aging: Did We Get the Story Wrong
May 18, 2026
Unknown duration
Measuring and Modifying Biological Age: What the Science Actually Shows
May 4, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 6/29/26 | Dr. Rich Miller: “There Are No Biomarkers of Aging” | 🧠 Episode OverviewWhat if “biological age” as a single number is the wrong way to think about aging?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Rich Miller at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Miller is a Professor of Pathology at the University of Michigan and one of the leaders of the Interventions Testing Program, the gold standard for testing longevity interventions in genetically diverse mice.This conversation challenges some of the biggest assumptions in longevity science: biomarkers of aging, cellular senescence, the search for one cause of aging, and the idea that mouse lifespan results automatically translate into human recommendations.The central message:Aging is not one pathway, one biomarker, or one number.The real question is not simply what causes aging.The real question is what can postpone many forms of age-related decline at the same time.🔑 KeywordsRichard Miller, Interventions Testing Program, ITP, aging biology, longevity science, geroscience, biological age, biomarkers of aging, aging-rate indicators, anti-aging drugs, geroprotectors, rapamycin, acarbose, ergothioneine🧠 Takeaways• Aging should not be reduced to one cause, one pathway, one biomarker, or one biological age number.• Rich Miller argues that the key question is not what causes aging, but what postpones many forms of age-related damage at once.• Lifespan is useful because it is definitive, but a true anti-aging drug should also delay multiple forms of functional decline.• Most proposed longevity interventions fail when tested rigorously.• Biomarkers of aging and aging-rate indicators are not the same thing.• A biomarker may change with age. An aging-rate indicator should tell us whether aging is moving faster or slower.• “Biological age” as a single number may hide important differences across tissues, systems, and disease risks.• Ergothioneine is intriguing in slow-aging mice, but it is not yet clear whether it is causal or simply a marker of a broader metabolic state.• Sex differences matter. Some interventions work in male mice but not female mice.• Rapamycin and acarbose are exciting in mice, but they are not proven human longevity drugs.• No drug has yet been proven to extend human lifespan by slowing aging itself.🎙️ The ReProgram PerspectiveThe ReProgram lens is simple:Mechanism over marketing.Outcomes over biomarkers.Trade-offs over hype.This episode is a reminder that longevity science needs both ambition and restraint.A compound that changes a biomarker has not necessarily slowed aging.A drug that extends lifespan in mice is not automatically safe or effective for humans.And a single “biological age” number may not capture the complexity of how real people age.Rich Miller’s message is not that aging biology is impossible.It is that the field has to be precise about what the data actually prove.The future of longevity science depends on rigorous testing, better endpoints, genetic diversity, sex-specific biology, and a clear distinction between promising mechanisms and proven outcomes.Chapters00:00 Are There Really Biomarkers of Aging?02:09 Dr. Rich Miller’s Origin Story03:24 How His Views on Aging Changed04:21 How Rich Miller Defines Aging and Its Complexities05:48 The Interventions Testing Program (ITP)07:31 What Is a True Anti-Aging Drug?08:37 Longevity Signatures and Metabolites10:33 The Role of Ergothionine in Aging13:17 Biomarkers vs Aging-Rate Indicators16:26 Sex Differences in Aging Research19:11 The Importance of Genetically Diverse Models22:09 Advocating for Aging Research23:45 Aging Research and Cancer25:19 Disease Silos in Science27:11 Rich Miller’s Own Longevity Habits29:51 The Risk of Rapamycin Self-ExperimentationNotesThe Interventions Testing Program (ITP): https://www.nia.nih.gov/research/dab/interventions-testing-program-itpDr. Rich Miller Lab: https://www.richmillerlab.com/ | — | ||||||
| 6/15/26 | GLP-1 Agonists and Longevity: The First ReProgram Scorecard | 🧠 Episode OverviewAre GLP-1 agonists longevity drugs?Not weight loss drugs.Not cosmetic drugs.Not simply appetite drugs.In this episode of The ReProgram, Dr. George Murphy launches a new recurring format: The ReProgram Scorecard — a science-first framework for grading popular longevity interventions through the same lens every time:Mechanistic plausibility.Human evidence.Magnitude of likely benefit.Safety and downside risk.Who may benefit most.Who should be cautious.Cost and accessibility.Longevity hype risk.And the final ReProgram grade.🔑 KeywordsGLP-1 agonists, GLP-1 and longevity, semaglutide, Ozempic, tirzepatide, metabolic health, healthspan, aging biology, inflammation, brain aging, cognitive decline, neuroinflammation, neuronal resilience, longevity medicine, geroscience, The ReProgram Podcast, Dr. George Murphy.🧠 Takeaways• GLP-1 agonists should not be understood only as weight-loss drugs. • GLP-1 agonists are not yet proven to slow biological aging, extend lifespan, reverse aging clocks, prevent frailty, or broadly preserve function across all older adults.• The magnitude of likely benefit is highly context-dependent. People with obesity, insulin resistance, type 2 diabetes, cardiovascular risk, fatty liver disease, metabolic syndrome, or inflammation linked to metabolic dysfunction may benefit most.• For metabolically healthy people using GLP-1 agonists purely as longevity hacks, the benefit is much less clear.• Safety matters. These are real drugs with real side effects, and they should not be treated as casual wellness supplements.• Lean mass preservation is critical. Weight loss without attention to resistance training, protein intake, and muscle maintenance may undermine long-term resilience, especially in older adults.🎙️ The ReProgram PerspectiveThe ReProgram lens is clear:Mechanism over marketing.Evidence over anecdotes.Trade-offs over hype.GLP-1 agonists are not magic. They are not proven anti-aging drugs. And they should not be marketed as universal longevity tools. But they also should not be dismissed as simple weight-loss drugs.📊 The ReProgram ScorecardMechanistic plausibility: 4.5 / 5Strong aging-relevant biology: metabolism, inflammation, cardiovascular risk, immune tone, and potentially neuronal resilience.Human evidence: 3.5 / 5 Strong for cardiometabolic outcomes. Promising but incomplete for longevity, resilience, and cognitive decline.Magnitude of likely benefit:4 / 5 in high-risk metabolic populations. 2.5–3 / 5 for broad longevity use.Safety and downside risk: 3 / 5 Useful drugs, but real side effects, medical supervision required, and muscle preservation matters.Who may benefit most: People with obesity, type 2 diabetes, insulin resistance, cardiovascular risk, fatty liver disease, metabolic syndrome, or inflammation linked to metabolic dysfunction.Who should be cautious: People with low muscle mass, frailty, eating disorders, certain GI or pancreatic/gallbladder risks, pregnancy considerations, relevant endocrine cancer risks, or anyone using unregulated versions.Cost and accessibility: 2 / 5 Major barrier.Longevity hype risk: High The biology is real, but the public narrative is ahead of the evidence.Final ReProgram Grade: B+Chapters00:00 Are GLP-1 Agonists Longevity Drugs?01:03 Introducing The ReProgram Scorecard02:02 What Are GLP-1 and Incretin-Based Therapies?03:33 Mechanistic Plausibility: Why GLP-1 Biology Matters for Aging06:27 Human Evidence: Cardiometabolic Healthspan vs. Longevity Proof08:45 Magnitude of Benefit: Who Has the Most Room to Improve?10:52 Safety, Side Effects, and Lean Mass Concerns14:04 Identifying Who May Benefit Most15:09 Who Should Be the Most Cautious in Using These Drugs?16:18 Cost and Accessibility Challenges17:20 Longevity Hype Risk19:34 Potential Cognitive Benefits of GLP1 Agonists22:17 Final ReProgram Scorecard for GLP1 Agonists24:10 Final Verdict on GLP1 Agonists and Future Directions | — | ||||||
| 6/1/26 | Can AI Decode Human Aging? | ReProgram Episode 14AI and Longevity: Hype, Hope, and the Biology of Aging🧠 Episode OverviewWhat if your doctor could look at your bloodwork, medical history, genome, proteins, metabolites, microbiome, and health trajectory - and tell you more than whether you are sick today?Can artificial intelligence decode human aging?AI will not magically cure aging. It will not replace biology. And it will not tell us exactly how to live forever.But it may help us do something incredibly important:See patterns in human aging that are too complex for the human mind to detect alone.In this episode of The ReProgram, Dr. George Murphy explores the real promise of AI in longevity science — and where the hype goes wrong.Aging is not one gene, one pathway, one biomarker, or one supplement. Aging is a moving, interacting network across time.That is why AI matters.But prediction is not understanding.A biomarker is not an outcome.And an AI-generated recommendation is not automatically personalized medicine.The future is not AI instead of biology.It is AI plus biology.🧠 Takeaways• AI will not magically cure aging, but it may become one of the most powerful tools for organizing biological complexity.• Aging is not a single pathway, gene, biomarker, or intervention. It is a dynamic network that changes over time.• The most useful question is not simply whether AI can predict aging, but whether AI can help us understand, measure, and eventually preserve resilience.• AI can identify patterns across massive datasets, but pattern recognition is not the same as biological truth.• Prediction is not understanding. An AI model may predict risk without explaining the mechanism behind that risk.• Bad data plus powerful AI does not create truth. It creates confident noise.• AI-generated health recommendations are not automatically personalized medicine; they may be personalized guesses delivered with confidence.• The future of longevity science is not AI instead of biology. It is AI plus biology.• The winning formula is: AI plus longitudinal human data plus functional biology plus clinical outcomes.🎙️ The ReProgram PerspectiveThe ReProgram lens is clear:AI is a tool.Biology is the reality.Health is the outcome.AI should not be dismissed as hype, because it is already changing scientific work. It is being used in data analysis, bioinformatics, coding, experimental design, literature review, hypothesis generation, logic checking, and the interpretation of large-scale biological datasets.But AI should also not be treated as magic.In longevity science, a correlation is not enough. A biomarker can correlate with age and still not drive aging. A biological age number can move after an intervention and still not prove that healthspan improved. A predictive model can sound authoritative and still fail to explain what is happening biologically.That is why this episode argues for grounded optimism.Be excited about AI.Be skeptical of overclaims.Demand validation.Ask whether predictions connect to mechanisms.Ask whether mechanisms connect to outcomes.Ask whether outcomes improve human lives.The future is not AI replacing biology.The future is AI helping us ask better biological questions — and then testing those questions in the lab and the clinic.Office Artifact:On the desk: GATTACA on DVD; 1997; IMDb7.7Chapters00:00 The Promise of AI in Longevity02:02 Why AI and Longevity are Both Exciting and Overhyped03:36 AI in the Lab, Not Science Fiction05:01 Aging is a Network That Changes Over Time06:35 Patterns in Aging and AIs Role09:11 Understanding Mechanisms Behind Predictions12:04 AI + Experimentation = Success14:37 The Hype vs. Reality of AI in Longevity17:18 The Future of AI in Longevity Medicine18:54 Personalizing Longevity with AI21:07 The Future: AI and Human Biology Connection | — | ||||||
| 5/18/26 | NAD and Aging: Did We Get the Story Wrong | ReProgram Episode 14The NAD Myth? What the New Human Data Really Say🧠 Episode OverviewIn this episode of The ReProgram, Dr. George Murphy takes a critical but balanced look at one of the most popular ideas in the longevity space:That NAD levels decline with age — and that boosting NAD may help slow aging.But new human data challenge one of the most common assumptions behind the NAD story:Whole-blood NAD levels may not decline with age.This episode explores what that finding means — and what it does not mean.The central takeaway:NAD is not dead.But the simplistic NAD longevity story needs a reset.🔑 KeywordsNAD, NAD+, aging, longevity, NR, NMN, NAD boosters, nicotinamide riboside, nicotinamide mononucleotide, mitochondrial function, DNA repair, sirtuins, PARPs, CD38, cellular metabolism, biological aging, healthspan, resilience, recovery capacity, inflammation, stress response, biomarker, whole-blood NAD, NAD decline, NAD supplements, NAD IV therapy, metabolism, cellular stress, anti-aging supplements, longevity science, The ReProgram Podcast🧠 Takeaways• NAD is essential biology, but it should not be treated as a magic anti-aging molecule.• New human data challenge the idea that whole-blood NAD levels universally decline with age.• Raising blood NAD is not the same thing as proving that aging has slowed.• NAD biology is likely tissue-specific, disease-specific, stress-specific, and context-dependent.• Blood NAD is not necessarily a reliable window into NAD metabolism in muscle, brain, liver, immune cells, or other tissues.• NAD boosters like NR and NMN can raise NAD-related metabolites, but that does not automatically mean they improve healthspan or longevity.• The most honest current framing is that NAD boosters are biologically plausible, biomarker-active, and clinically unproven as general longevity therapies.• NAD may be more relevant in specific contexts of stress, disease, frailty, metabolic dysfunction, or impaired recovery than as a universal supplement for healthy people.• NAD infusions and high-cost wellness protocols deserve extra skepticism because the marketing often exceeds the evidence.• Longevity interventions should be judged by function, resilience, healthspan, and clinical outcomes — not by biomarker movement alone.🎙️ The ReProgram PerspectiveNAD biology matters, but the public story has become too simple.The key question is not whether we can raise NAD. The key question is whether doing so improves function, resilience, recovery, disease risk, or healthspan.Blood biomarkers can be useful, but they are not outcomes. Aging biology is not a supplement slogan.The ReProgram lens is clear: mechanism over marketing, outcome data over anecdotes, and trade-offs over hype.Chapters00:00 The NAD Longevity Story Just Changed01:24 What NAD Is and Why It Matters03:31 NAD as Cellular Currency04:37 The Old Model: Aging, Inflammation, and NAD Decline06:32 The New Human Data on Whole-Blood NAD08:30 Why Blood NAD Is Not the Whole Story11:01 NAD Boosters: What They May Actually Do12:58 NAD Boosters remain Scientifically Interesting14:39 NAD Boosters: Limitations16:55 Should You Take NAD for Longevity?19:28 The ReProgram Takeaway: NAD Is Not Dead, But the Hype Needs a ResetNotes: Nature Metabolism Paper: Human whole-blood NAD+ levels do not vary with age or lifestyle interventions: https://www.nature.com/articles/s42255-026-01537-5Cell Metabolism Paper: NAD depletion in skeletal muscle does not compromise muscle function or accelerate aging: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00212-8 | — | ||||||
| 5/4/26 | Measuring and Modifying Biological Age: What the Science Actually Shows | ReProgram Episode 13🧠 Episode OverviewWhat does it actually mean to measure your biological age—and can it be changed? In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Jesse Poganik, a leading scientist in the field of biological aging clocks and biomarkers of aging. Together, they unpack the science behind biological age—how it’s measured, what it reflects, and whether it represents a causal driver of aging or simply a readout of deeper biological processes. This conversation goes beyond the hype. It explores the emerging tools used to quantify aging, the limitations of current approaches, and what it will take to translate these measurements into meaningful clinical interventions. From organ transplantation to immune system signaling, Dr. Poganik shares how real-world biological systems are helping decode the mechanisms that shape how we age.🔑 Keywordsbiological age, epigenetic clocks, aging biomarkers, DNA methylation, longevity science, healthspan, resilience, systems biology, immune aging, biomarkers of aging, translational medicine, aging mechanisms, clinical biomarkers, longevity interventions🔬 What You’ll Learn• What “biological age” actually measures—and what it doesn’t • How epigenetic clocks are built and why they’ve gained traction • The difference between correlation and causation in aging biomarkers • Why systemic signals (like blood and immune factors) may regulate aging • How organ transplantation provides a natural experiment in aging biology • The biggest challenges in bringing biological age testing into the clinic • What standardization efforts (like the Biomarkers of Aging Consortium) aim to solve • Whether modifying biological age is currently possible—and what’s coming next 🎙️ The ReProgram PerspectiveBiological age is not just a number to optimize.It is a signal—one that reflects deeper biological processes we are only beginning to understand.The challenge is not simply to measure aging more precisely. The challenge is to determine whether those measurements represent something we can actually change.Because longevity is not about chasing metrics.It is about understanding the biology those metrics reflect and ultimately, learning how to influence it.🎧 Final ThoughtWe can now measure aging with increasing precision.But the real question remains:Are we measuring something we can change—or something we still don’t fully understand?Office Artifact: On the desk: Steampunk Pocket WatchChapters00:00:00 Introduction to Measuring and Modifying Biological Age00:04:07 Defining Biological Age00:04:03 Epigenetic Clocks and Their Role in the Evolution of the Field00:10:02 Causality in Aging Biomarkers00:12:47 Clinical Applications of Biological Age00:16:08 Nutritional Interventions and Biological Age00:19:00 Understanding Aging Signatures00:21:35 Transient Changes in Biological Age00:24:27 Heterochronic Transplantation Studies00:27:26 Blood as the Conduit of Aging or Rejuvenation Factors00:30:25 Longitudinal Data in Organ Transplantation00:33:23 The Biomarkers of Aging Consortium00:36:25 The Birth of the Biomarkers of Aging Consortium00:40:06 Personal Reflections on Aging and Longevity00:41:47 Wrap Up and Putting It All TogetherNotes: Jesse Poganik, PhD: https://www.poganik.com/Biomarkers of Aging Consortium: https://www.agingconsortium.org/The inaugural collaborative manuscript of the Biomarkers of Aging Consortium was published in Cell: https://www.cell.com/cell/fulltext/S0092-8674(23)00857-7Landmark Horvath Biological Age Paper: https://pubmed.ncbi.nlm.nih.gov/24138928/Clinical Trials Using Biomarkers of Aging: CALERIE: https://clinicaltrials.gov/study/NCT00427193DO-HEALTH: https://do-health.eu/about/trial/COSMOS Multivitamin Trial: https://cosmostrial.org/ | — | ||||||
| 4/20/26 | The Biology of Recovery: Why Adaptation Fails in Modern Life | ReProgram Episode 12Most people think they need to do more.Train harder. Push further. Add more stimulus.But what if the real problem isn’t effort…What if your body can no longer recover from what you’re already doing?In this episode of The ReProgram, Dr. George Murphy reframes aging, performance, and longevity through a different lens:Recovery capacity.Rather than viewing aging as simple decline, this episode explores a more fundamental idea:that aging is the progressive loss of dynamic resilience—your ability to recover from stress.Because adaptation doesn’t come from what you do.It comes from what your body can recover from.If you’re training hard but not progressing…If you’re doing more but getting less back…If fatigue is accumulating instead of resolving…The issue may not be effort.It may be recovery.This episode breaks down:• What recovery actually is (and why it’s not passive) • Why modern life disrupts recovery at a systems level • The biological relationship between stress, adaptation, and repair • Why increasing effort can sometimes accelerate decline • How to recognize when recovery—not stimulus—is the limiting factor • A new framework for thinking about aging, resilience, and long-term function This is not a conversation about doing less.It’s a conversation about aligning what you ask of your body with what it can actually recover from.Because ultimately, resilience is not defined by how much stress you can endure—It’s defined by how well you can recover.🔑 Keywordsrecovery, resilience, aging, longevity, adaptation, stress, recovery capacity, overtraining, fatigue, burnout, performance plateau, healthspan, systems biology, metabolic health, sleep, training, exercise physiology, nervous system, hormesis, modern stress, biological resilience🧠 Takeaways• Recovery is not passive—it is an active biological process that determines whether stress leads to adaptation or breakdown.• The body does not adapt to what we do; it adapts to what it can recover from.• Aging can be understood as the progressive loss of dynamic resilience—the ability to recover from disruption.• When recovery capacity declines, increasing effort often worsens outcomes rather than improving them.• Many modern stressors impair recovery by preventing full resolution of physiological strain.• Sustainable progress depends on aligning stimulus with recovery capacity, not maximizing input.🎙️ The ReProgram PerspectiveRecovery is not the absence of effort.It is the biological process that makes effort meaningful.When recovery capacity is preserved, the body remains adaptable, responsive, and capable of maintaining function over time.But when that capacity declines, even the right inputs fail to produce the desired outcome.Longevity, therefore, is not simply about extending time—It is about preserving the ability to recover within that time.Office Artifact:On the desk: Funko Toys, Pop Movies Tron 489Chapters00:00:00 Understanding Recovery and Aging00:01:35 Aging as Loss of Dynamic Resilience00:04:03 The Importance of Recovery Capacity00:06:28 A Personal Shift: From Training to Recovery00:08:43 Why Modern Life Disrupts Recovery00:11:18 Recognizing Signs of Under-Recovery00:13:29 The Signals of Recovery and Adaptation00:15:53 Strategies for Effective Recovery00:18:12 Closing: Redefining Resilience | — | ||||||
| 4/6/26 | Muscle, Strength and The Biology of Staying Capable | In this episode of The ReProgram, Dr. George Murphy reframes skeletal muscle as far more than tissue for movement or aesthetics.Muscle is one of the body’s most powerful regulators of metabolic stability, resilience, recovery, and long-term functional independence.This conversation explores why the loss of muscle with age is not simply about weakness—it is a systems-level shift that affects glucose regulation, balance, neuromuscular coordination, recovery from stress, and ultimately how aging is experienced.Dr. Murphy breaks down the biology of sarcopenia, the profound role of resistance training across the lifespan, and why it is never too late to restore meaningful strength and function.The episode also challenges a common myth in aging:that we should reduce challenge as we get older.Instead, the real goal is intelligent, appropriately scaled resistance that preserves the biological signals required for adaptation.This is not a conversation about physique.It is a conversation about remaining capable.About preserving the systems that allow us to move through the world with confidence, recover from disruption, and maintain independence for as long as biology allows.🔑Keywordsmuscle, skeletal muscle, strength, longevity, resistance training, sarcopenia, healthy aging, healthspan, neuromuscular aging, frailty, metabolism, glucose regulation, muscle loss, functional aging, independence, resilience, exercise science, late-life training, muscle physiology, healthy lifespan🧠 Takeaways• Skeletal muscle is not cosmetic tissue—it is biological infrastructure for metabolism, recovery, and resilience.• Aging is experienced through loss of function, and muscle is one of the most modifiable systems that shapes that trajectory.• Resistance training remains effective across the lifespan, even when initiated later in life.• “Heavy” is relative to current capacity—the goal is intelligent challenge, not maximal load.• Strength reflects integrated systems biology, including muscle quality, neural coordination, and recovery capacity.• Longevity is ultimately about preserving capability, independence, and the ability to engage with life on your own terms.🎙️ The ReProgram PerspectiveMuscle is not about aesthetics.It is the biological infrastructure of capability.When we challenge it intelligently, we are not chasing strength for its own sake—we are preserving the systems that allow us to remain independent within time.Office Artifact:On the desk: Handexer digital hand dynamometer: https://www.amazon.com/Handexer-Strengtheners-Dynamometer-Measurement-Electronic/dp/B0B1LNFSVB/ref=ast_sto_dp_puis?th=1Chapters00:00:00 The True Role of Muscle in Aging00:02:26 Redefining Muscle Beyond Aesthetics00:03:20 Muscle as a Metabolic Regulator00:05:19 Muscle Contributes to Longevity in Multiple Ways00:07:24 Understanding Sarcopenia and its Implications00:08:15 The Power of Resistance Training00:12:18 Intensity and Resistance Training for Aging00:16:22 The Neurological Aspect of Strength00:21:41 Conclusion: Putting It All Together | — | ||||||
| 3/23/26 | Peptides for Longevity: What No One Tells You About Anti-Aging | In this episode—Part 3 of the Peptides 101 series—we move beyond healing and performance to examine one of the most compelling and misunderstood frontiers in modern medicine: longevity and anti-aging peptides.But this is where the conversation changes.Because using peptides to recover from injury is fundamentally different from using them to modify the trajectory of aging itself.In this episode, we break down the biology behind commonly discussed longevity peptides—including Epitalon, MOTS-c, and Thymosin Alpha-1—through the lens of signaling, systems biology, and long-term risk.We explore critical pathways like mTOR, telomere dynamics, mitochondrial signaling, and immune regulation, and examine the central tension that defines aging biology:👉 The same signals that promote growth and repair early in life may accelerate disease later on.This episode is not about hype.It’s about mechanism, trade-offs, and the reality that biology does not offer intervention without consequence.🔑Keywordspeptides, anti-aging, longevity, mTOR, telomeres, mitochondria, cancer risk, regeneration, immune signaling, growth hormone, epitalon, MOTS-c, thymosin alpha-1, signaling, science, clinical trials, regenerative medicine, aging biology, healthspan🧠 Takeaways• Peptides are not supplements—they are biological signals that influence complex systems.• Longevity interventions aim to alter trajectory, not just restore baseline.• Growth signaling pathways (GH, IGF-1, mTOR) create a fundamental trade-off between repair and long-term risk.• Aging is not driven by a single pathway—it reflects interconnected biological systems under constraint.Epitalon (Telomere Biology)• Proposed to activate telomerase and influence cellular aging.• Telomerase is tightly regulated for a reason—uncontrolled activation is a hallmark of cancer biology.• Long-term human outcome data remains limited.MOTS-c (Mitochondrial Signaling)• A mitochondrial-derived peptide involved in metabolic regulation and stress response.• Shows promise in improving metabolic flexibility in animal models.• Early-stage science—not yet proven to impact human longevity outcomes.Thymosin Alpha-1 (Immune Modulation)• Influences immune signaling and has established clinical use in specific conditions.• Aging applications must consider the balance between immune activation and dysregulation.• Immune systems are not simply “boosted”—they are finely regulated networks.• Longevity is measured in decades—not weeks or months.• Short-term biomarker improvements do not equal long-term outcome benefits.• Increasing growth and survival signaling later in life introduces biological uncertainty—particularly in cancer risk.• The absence of long-term human data is not a minor gap—it is the central limitation.🎙️ The ReProgram PerspectivePeptides are powerful because they are instructions.And when you introduce new instructions into a system shaped by evolution, you inherit the trade-offs that evolution never eliminated.Curiosity is essential.But discipline is what protects long-term health.Office Artifact:On the desk: Yipwon/Garra Figure, Sepik River hardwood, representing nature spirits or ancestral power, Papua New Guinea, 2019Chapters00:00:00 Introduction to Peptides and Longevity00:00:51 Understanding Peptides as Signals00:03:39 The Biological Paradox of Growth Signaling00:05:08 mTOR and its Role in Aging Biology00:11:07 Exploring Longevity peptides: Epitalon, MOTS-c, and Thymic Peptides00:15:37 The Complexities of Growth Hormone Signaling00:17:23 The Scientific Position on Longevity Peptides00:21:10 Cancer Biology and Growth Signaling00:24:28 Conclusion: The Importance of Discipline in Longevity Research | — | ||||||
| 3/9/26 | The Secret Lives of Super Agers: What 100-Year-Olds Teach Us About Aging | ReProgram Episode 10In this insightful interview, Dr. Stacy Andersen, a behavioral neuroscientist and expert in aging research, shares her journey into the study of exceptional longevity, the characteristics of centenarians, and the biological and lifestyle factors that contribute to healthy aging. Discover how resilience to disease, genetic protective factors, and lifestyle choices intertwine to shape the future of longevity.Keywordslongevity, centenarians, healthy aging, resilience, genetics, lifestyle, Alzheimer's, cognitive health, aging researchTakeawaysResilience is key to aging well, focusing on quality of life over mere longevity. Diverse paths, including genetics and lifestyle, lead to exceptional aging. Longevity results from complex interactions between genes and behaviors. Cognitive resilience can stem from managing or avoiding pathologies. A sense of purpose significantly contributes to lifespan and health span. Centenarians exemplify how lifestyle, genetics, and purpose optimize healthspan.Office ArtifactOn the desk: Godzilla, MechaGodzilla and Ultraman, Bandai Toys, Tokyo, Japan, 2018Chapters00:00 Rethinking Aging: A New Perspective02:21 Dr. Andersen’s Journey Into Longevity Science04:32 Defining Exceptional Longevity05:51 Not All Centenarians Are Created Equal08:37 Characterizing Centenarians10:51 Cognitive Super Agers13:48 Resilience and Avoiding Aging-Related Disease18:08 Becoming Centenarian-like22:01 Purpose = Longevity22:56 Aging Is Not A Single TrajectoryResourcesThe New England Centenarian Study - https://www.bumc.bu.edu/centenarian/Jim Fries' Compression of Morbidity Hypothesis - https://en.wikipedia.org/wiki/Compression_of_morbidity Dr. Stacy Andersen's Research at Boston University - https://profiles.bu.edu/Stacy.Andersen | — | ||||||
| 2/23/26 | Can We Measure Aging? The Truth About Biological Aging Clocks | ReProgram Episode 9In this episode of the Reprogram podcast, Dr. George Murphy interviews Dr. Nicholas Skivir, an expert in biological aging clocks. They discuss the differences between biological and chronological age, the complexities of measuring aging, and the construction and application of biological aging clocks. The conversation delves into factors influencing biological age, the role of disease in aging, and the potential future applications of biological aging clocks in clinical practice. The episode emphasizes the importance of understanding biological age as a metric for health and longevity.Keywordsbiological aging, chronological age, aging clocks, epigenetic clocks, healthspan, longevity, regenerative medicine, aging research, biological metrics, disease modelingTakeawaysBiological age is a more physiological measure than chronological age.Aging clocks can predict health outcomes and morbidity.The construction of biological aging clocks involves various omics data.Epigenetic clocks are preferred due to their stability and reproducibility.Biological age can be influenced by lifestyle factors like diet and exercise.Disease can act as a driver of biological age in models.Future clinical practice may incorporate biological aging metrics.Understanding biological age can inform personalized medicine.The field of aging research is rapidly evolving with new models.Interpretability of biological aging clocks remains a challenge.Office ArtifactOn the desk: Bow and Quiver with Arrows; The sap of the Antiaris toxicaria tree is used to make arrow poison, historically used for hunting and warfare, Indonesia 2017Chapters00:00 Introduction to Biological Aging Clocks03:21 Understanding Biological vs. Chronological Age05:33 The Complexity of Measuring Aging06:35 Construction of Biological Aging Clocks10:51 Factors Influencing Biological Age14:57 Cellular Rejuvenation via Reprogramming16:47 Disease as a Driver of Biological Age17:51 What Clocks Do Well...and Don't Do Well20:02 The Future of Biological Aging in Medicine22:21 Practical Applications of Biological Aging ClocksResourcesSteve Horvath's Epigenetic Clock - https://en.wikipedia.org/wiki/Steve_HorvathDNA methylation arrays - https://www.illumina.com/ | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 2/9/26 | Peptides for Healing & Performance: BPC-157, TB-500 & Growth Hormone Explained | In this episode of Peptides 101, Dr. George Murphy delves into the application of peptide science in real-world scenarios, focusing on the distinction between peptides as signals versus supplements. He discusses the compelling nature of healing peptides, particularly BPC 157 and TB 500, and the importance of understanding the scientific evidence behind their use. The conversation emphasizes the gap between anecdotal claims and clinical data, urging listeners to approach peptide use with caution and humility. The episode concludes with a preview of future discussions on peptides related to aging and longevity.Keywordspeptides, healing, recovery, BPC 157, TB 500, growth hormone, regenerative medicine, healthspan, geroprotectors, longevityTakeawaysPeptides are signals that instruct cells, not supplements that provide direct benefits.Healing peptides are appealing due to the urgency created by injuries and chronic pain. BPC 157 is often marketed with exaggerated claims, leading to misconceptions about its efficacy.Human clinical data on BPC 157 is limited, with no large trials supporting its healing claims.TB 500 is framed as an amplifier of healing, but lacks substantial human trial evidence.Growth hormone signaling peptides are seen as safer alternatives but also require caution.The biological mechanisms of peptides are often plausible, but human outcome data is frequently lacking.Anecdotal evidence does not equate to scientific proof of efficacy.Office ArtifactOn the desk: Mongol archer on horseback, Ulaanbaatar, Mongolia 2018Chapters00:00:00 Understanding Peptides: Signals, Not Supplements00:03:06 The Emotional Appeal of Healing Peptides00:04:09 BPC 157: The Wolverine Metaphor and Its Implications00:06:57 The Reality of BPC 157: Signal Modulation vs. Tissue Regeneration00:09:12 The Absence of Human Clinical Data on BPC 15700:11:04 Exploring TB500: The Amplifier of Healing00:13:50 Risks and Negative Outcomes of Peptide Use00:15:19 Understanding TB500: Healing and Potential Concerns00:17:12 Growth Hormone Signaling Peptides: A Natural Alternative?00:21:35 What Scientists Worry about when GH and IGF1 Are Increased00:24:01 The Bigger Picture: Peptides and Human OutcomesPeer‑Reviewed References BPC-157 (Body Protection Compound)Key References (highly cited / widely referenced) + why they matter1. Huang et al., 2015 Wound Healing & AngiogenesisWhy it matters: One of the most frequently cited BPC-157 papers; combines animal injury models with cellular migration and blood-vessel formation assays.Drug Design, Development and Therapyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4425239/2. Grabarević et al., 1997 Nitric Oxide–Related SignalingWhy it matters: Early foundational work linking BPC-157 to nitric-oxide–associated pathways, frequently referenced in later mechanistic studies.Life Scienceshttps://pubmed.ncbi.nlm.nih.gov/9403788/TB-500 (Thymosin Beta-4 fragment / motif) Key References (highly cited / widely referenced) + why they matter1. Philp et al., 2004 — Tβ4 promotes angiogenesis, wound repair, hair-related effects in animal models (~183 citations).https://pubmed.ncbi.nlm.nih.gov/15037013/ 2. Philp et al., 2003 — Mechanistic paper tying Tβ4 to angiogenesis and endothelial behavior (~162 citations).https://pubmed.ncbi.nlm.nih.gov/14500546/ Growth-hormone (GH) signaling peptides (CJC-1295 / Tesamorelin / Ipamorelin + “GHRPs” broadly)Key References (highly cited / widely referenced) + why they matter1. Kojima et al., 1999 (Nature) — discovery of ghrelin (~12,044 citations): foundational to the whole “GHRP/ghrelin receptor” conversation.https://www.nature.com/articles/45230 2. Ghigo et al., 1997 — classic review on GH-releasing peptides (~634 citations): widely used overview of the GHRP class.https://pubmed.ncbi.nlm.nih.gov/9186261/ | — | ||||||
| 1/26/26 | Peptides 101: The Biology Behind the Hype | The ReProgram Episode 8A: The first in a 3 part series In this episode, Dr. George Murphy delves into the world of peptides, exploring their scientific basis, the misconceptions surrounding them, and the importance of understanding their structure and function. He discusses the differences between natural and synthetic peptides, the manufacturing process, and the potential risks associated with peptide use. The conversation aims to provide clarity in a landscape filled with hype and misinformation, setting the stage for future discussions on specific peptides and their claims.Keywordspeptides, science, health, longevity, biochemistry, molecular biology, regenerative medicine, risks, benefits, healthspan, geroprotectors, longevityTakeawaysPeptides are being marketed as shortcuts to health benefits.Understanding peptides requires knowledge of their structure and function.The same term 'peptides' can refer to both regulated medicine and unregulated products.Peptides can have unintended effects if not properly understood.Natural peptides are often modified for better efficacy, which changes their behavior.Manufacturing quality is crucial for peptide effectiveness and safety.Contaminated or poorly manufactured peptides can pose serious health risks.Social media often emphasizes benefits without discussing potential failures.Science focuses on understanding risks and failure modes in peptide use.Future episodes will explore specific peptides and their claims.Office ArtifactOn the desk: Polynesian Tiki, a representation of a half-human, half-god figure symbolizing protection, strength, and ancestral connection, Morea, French Polynesia 2021 Chapters00:00:00 Introduction to Peptides: The Current Landscape00:01:56 Understanding Peptides: Science vs. Hype00:03:46 The Structure and Function of Peptides00:06:58 Natural vs. Designed Peptides00:10:06 Where Off Target Effects Enter the Picture00:11:21 The Production and Quality of Peptides00:15:20 Risks and Negative Outcomes of Peptide Use00:16:59 Looking Ahead: Peptides 101: Parts 2 & 3 | — | ||||||
| 1/12/26 | Ozempic Isn’t a Weight-Loss Drug | The Real Science of GLP-1s | The ReProgram Episode 7In this episode of the Reprogram Podcast, Dr. George Murphy explores the rise of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, discussing their mechanisms, effects on metabolism, and implications for aging and healthspan. He emphasizes that these drugs are not merely weight loss solutions but agents that act on multiple organs to reprogram how the body regulates energy and hunger. The conversation also addresses the potential benefits and drawbacks of these drugs, including their impact on muscle mass and overall health.KeywordsGLP-1 drugs, Ozempic, Wegovy, Mounjaro, weight loss, metabolic health, aging, healthspan, geroprotectors, longevityTakeawaysAlmost everyone knows someone on a GLP-1 drug.These drugs feel like a miracle for some, unsettling for others.GLP-1 drugs are not just weight loss drugs; they reprogram energy regulation.The rapid adoption of GLP-1 drugs reveals widespread metabolic dysfunction.GLP-1 drugs improve blood sugar control and reduce cardiovascular events.Weight loss is a visible effect, but metabolic changes are deeper.GLP-1 drugs may act as geroprotectors by improving healthspan.Muscle loss is a significant concern with GLP-1 drugs.Combining pharmacology with resistance training may yield the best outcomes.The future of aging involves knowing when to use drugs versus lifestyle changes.Office ArtifactOn the desk: Commemorative souvenirs from the Sumo World Championships, Ohama Sumo Stadium, Sakai City, Osaka, Japan 2019 Chapters00:00:00 Introduction to GLP-1 Drugs and Their Impact00:02:13 How Widespread is the Use of GLP-1 Drugs?00:03:35 What Are GLP-1 Drugs and How Do They Work?00:06:43 Weight Loss vs. Metabolic Reprogramming00:09:23 GLP-1 Drugs as Potential Geroprotectors00:12:31 Drawbacks and Considerations of Taking GLP-1 Drugs00:14:55 GLP-1 Drugs, Metabolism, and the Future of Aging | — | ||||||
| 12/29/25 | Inside the Aging Brain: Dementia, Resilience, and What We Can Do! | Episode 6 This episode of the ReProgram podcast, featuring Dr. Benjamin Wolozin, delves into the complexities of neurodegenerative diseases and brain aging, with a focus on Alzheimer's. The discussion covers the diversity of these diseases, diagnostic challenges, and the future of research. The conversation is enriched with personal stories and expert insights, providing a comprehensive understanding of the topic.Keywordsmemory, aging, dementia, Alzheimer’s, cognitive health, sleep, phospho-tau, biomarkers, cognitive decline, health tests, longevityTakeawaysUnderstanding the diversity of neurodegenerative diseases is crucial.Early diagnosis of Alzheimer's remains a significant challenge.Research is advancing, but there's still a long way to go.Personal stories provide valuable insights into the impact of these diseases.The role of genetics in neurodegeneration is complex and multifaceted.Public awareness and education are key to addressing these diseases.Innovative research methods are being developed to tackle Alzheimer's.Collaboration among scientists is essential for progress.Funding and grant writing are critical components of research.There is hope for future breakthroughs in treatment and diagnosis.Office ArtifactOn the desk: The Vietnamese conical hat called Nón lá (pronounced "non lah"), meaning "leaf hat," made from palm leaves and bamboo, serving as a cultural symbol and protection from sun/rain. Hanoi, VietnamChapters00:00:59 Dr. Benjamin Wolozin’s Journey into Neuroscience00:04:19 What is Alzheimer’s Disease and How Do We Define It?00:09:35 Cognitive Decline and Aging00:11:07 Heart Health is Brain Health00:12:01 Challenges in Alzheimer’s Drug Development00:16:14 The Role of Biomarkers in Diagnosis00:19:54 Genetics vs. Environment in Neurodegenerative Disease00:22:22 Know Your Genetics By Observing Your Family!00:25:02 Targeting Aging to Prevent Neurodegeneration00:29:04 Grant Funding and the Future of Research00:33:52 Optimism for Future Therapies | — | ||||||
| 12/16/25 | The Rise of Longevity Clinics | Episode 5 In this episode of the Reprogram podcast, Dr. George Murphy explores the burgeoning world of longevity clinics, particularly in Thailand, where anti-aging treatments have become mainstream. He delves into the science behind stem cell therapies, the rise of IV drip bars, and the booming aesthetic dermatology industry. The conversation highlights the accessibility and affordability of these treatments in Thailand, while also addressing the potential pitfalls and the importance of navigating this landscape with caution. Ultimately, the episode emphasizes the need for a balanced understanding of longevity science and the commercial industry surrounding it, advocating for patient safety and informed decision-making.Keywordslongevity, anti-aging, Thailand, stem cells, IV drips, aesthetic treatments, wellness tourism, regenerative medicine, aging biology, healthTakeawaysLongevity clinics are becoming mainstream, especially in Thailand.Thailand is strategically positioned as a global medical wellness destination.Stem cell therapies have legitimate applications but are often misrepresented.IV drip bars offer hydration but may not provide significant health benefits.Laser treatments can produce meaningful results when performed by skilled practitioners.The Brotox movement reflects changing attitudes towards men's aesthetics.Thailand's longevity industry is characterized by accessibility and affordability.Consumers must be cautious of over-promising marketing in the longevity space.Questions about treatment safety and efficacy are crucial for informed decisions.Scientific breakthroughs in aging are emerging, but the industry is still evolving.Chapters00:00:00 Welcome to the Future of Longevity Clinics00:02:35 Thailand: The Global Hub for Longevity Treatment00:05:26 Understanding Stem Cell Therapies00:09:13 The Rise of IV Drip Bars00:13:05 Laser Treatments and Aesthetic Dermatology00:15:58 The Brotox Movement: Men Embracing Aesthetics00:19:21 What Thailand Gets Right in Longevity Medicine00:22:16 Navigating the Pitfalls of Longevity Treatments00:25:34 The Future of Longevity Science vs. Industry | — | ||||||
| 12/1/25 | Why Eating Less Slows Aging | Caloric Restriction & Longevity with Dr. Rozalyn Anderson | Episode 4 In this episode of the Reprogram Podcast, Dr. George Murphy hosts Dr. Rozalyn Anderson, a leading expert in caloric restriction and metabolism and how they impact healthful aging. They delve into the science of aging, focusing on caloric restriction and its impact on longevity. Dr. Anderson shares her journey from yeast genetics to studying aging in animal models, and finally, to applying what was learned to humans, highlighting the metabolic processes that contribute to aging and how caloric restriction can delay age-related diseases. The discussion also covers the potential of geroprotectors like rapamycin, the possibilities of radical age reversal, and how we should train the next generation of scientists and clinicians.Keywordscaloric restriction, aging, metabolism, longevity, geroprotectors, rapamycin, geroscience, regenerative medicine, aging biology, gerontology TakeawaysCaloric restriction is the gold standard for studying longevity interventions.Metabolism plays a crucial role in aging processes.Caloric restriction can delay the onset of age-related diseases.Rapamycin shows promise as a geroprotector.Energy efficiency is key to metabolic resilience.Human trials like CALERIE align with animal studies on aging.Methylation clocks offer insights into biological age.Functional outcomes are vital in aging research.Geroprotectors aim to offset age-related conditions.Collaboration between academia and industry is essential.Office ArtifactOn the desk: The Mongkhon or Muay Thai Headband traditionally worn by Thai martial artist as they enter the ring. Bangkok, ThailandChapters00:00:00 Introduction to Dr. Rozalyn Anderson and Caloric Restriction00:03:04 Understanding Caloric Restriction00:06:44 We Are What We Eat!00:08:38 Caloric Restriction as the “Gold Standard’ of Slowing Aging00:10:03 Rapamycin as a Longevity Intervention00:11:30 Exploring Geroprotectors00:14:48 What is Aging and How Do We Measure It?00:16:40 Defining Geroprotection and Longevity00:18:55 The Role of the NIH in Aging Research00:22:12 Collaboration Between Academia and Industry00:23:38 The Realities of Age Reversal00:26:33 Personal Reflections on Aging and LifestyleNotes:The Interventions Testing Program (ITP): https://www.nia.nih.gov/research/dab/interventions-testing-program-itpThe National Institute on Aging: https://www.nia.nih.gov/ | — | ||||||
| 11/17/25 | What Centenarians Teach Us About Living Longer | Dr. Tom Perls | Episode 3 In this episode of the Reprogram podcast, Dr. George Murphy hosts Dr. Tom Perls, a leading expert in human exceptional longevity. They discuss Dr. Perls' journey into gerontology, the New England Centenarian Study, and the factors contributing to exceptional longevity. The conversation covers the genetic and environmental influences on aging, the role of centenarians in understanding longevity, and practical advice for living a centenarian-like life.Keywordslongevity, centenarians, aging, health, resilience, exceptional aging, gerontology, aging research, genetics, healthspanTakeawaysDr. Tom Perls shares his journey into gerontology and exceptional longevity.The New England Centenarian Study is the largest study of centenarians and their families.Centenarians often defy the expectation that older age equates to poorer health.The majority of centenarians are female, with unique resilience against age-related diseases.Genetic and environmental factors both play significant roles in longevity.The concept of 'escapers' who avoid age-related diseases is explored.Dr. Perls introduces the 'Sageing' acronym for healthy aging practices.Lifestyle choices can influence longevity and healthspan.The potential for future therapeutics to extend life is discussed.Avoid smoking and anti-aging quackery for better health.Optimism about aging can motivate healthier choices.Office ArtifactOn the desk: Original artwork composed of rolled magazine pages, Bali, IndonesiaChapters00:00 Introduction to Longevity and Exceptional Aging01:07 Dr. Perls’ Journey into Gerontology and Exceptional Longevity05:57 Defining Exceptional Longevity08:49 Gender Differences in Centenarians14:50 The Centenarian Boom and Population Trends19:53 Stratifying Centenarians: Survivors, Delayers, and Escapers25:28 Genetics vs. Environment in Longevity32:23 Becoming Centenarian-like37:07 The SAGEING framework for Healthy Aging45:40 Anti-aging Quackery48:23 Future of Longevity Science52:41 Lesson from Centenarians | — | ||||||
| 11/17/25 | What Is Aging—And Can Science Really Reverse It? | Episode 2 In this episode of the Reprogram podcast, Dr. George Murphy explores the enigmatic topic of aging, discussing its definitions, cultural significance, and the latest scientific advancements aimed at understanding and potentially reversing the aging process. The conversation delves into the historical obsession with aging, the current state of research, and the implications of emerging therapies.Keywordsaging, science, medicine, longevity, epigenetics, biological clocks, senescence, gene therapy, regenerative medicine, immortality, geroscienceTakeawaysAging is a complex and mysterious process and is defined variably by different scientists.Modern science is exploring senolytic drugs and gene therapies.The hallmarks of aging provide a framework for understanding the process.Biological aging clocks are a tool for measuring age.Epigenetics play a key role in how we age.Aging is a universal process affecting everyone.Research is ongoing to find ways to slow or reverse aging.Age reversal is possible at the cellular level, but is not yet a reality for humans.Office ArtifactOn the desk: Ostrich egg from South AfricaChapters00:00 The Mystery of Aging03:01 Understanding Aging: Damage Accumulation and Resilience06:10 The Hallmarks of Aging08:54 Epigenetics: The Key to Biological Age12:11 Age Reversal: Resetting the SlinkyNotes:Seminal Hallmarks of Aging Paper: https://pubmed.ncbi.nlm.nih.gov/23746838/ | — | ||||||
| 11/17/25 | Stem Cells & Regenerative Medicine: What the Science Actually Supports | Episode 1 In this episode of the Reprogram podcast, Dr. George Murphy and Dr. Gustavo Mostoslavsky delve into the world of stem cells and regenerative medicine. They discuss the fundamental properties of stem cells, their classifications, and the controversies surrounding their use in treatments. The conversation highlights the groundbreaking discovery of induced pluripotent stem cells (iPSCs) and their potential therapeutic applications, as well as the emerging field of organoids. The episode emphasizes the importance of understanding the science behind stem cells, the ethical implications, and the need for patience as research progresses towards practical applications.Keywordsstem cells, regenerative medicine, iPSCs, pluripotent, adult stem cells, Shinya Yamanaka, bioartificial organs, stem cell tourism, gene editing, organoidsTakeawaysStem cells have two main properties: self-renewal and differentiation.Adult stem cells are found in tissues and organs, while pluripotent stem cells can become any cell type.iPSCs were discovered by Dr. Shinya Yamanaka, revolutionizing stem cell research.Ethical concerns exist around embryonic stem cells, but iPSCs offer a non-controversial alternative.Stem cell tourism exploits desperate patients with unproven treatments; Education and awareness are crucial to avoid falling for stem false claims.Organoids are miniaturized and simplified versions of organs created in vitro.iPSCs are used for disease modeling and have potential therapeutic applications.Gene editing, like CRISPR, is advancing stem cell research.Bioartificial organs could solve organ transplant shortages in the future.The field of stem cell research is rapidly advancing, with many clinical trials underway; The future of stem cell research holds promise for transformative therapies, but patience is needed.Chapters00:00 Introduction to Stem Cells and Regenerative Medicine02:21 Defining Stem Cells: Properties and Classifications07:52 Controversies in Stem Cell Treatments15:07 Induced Pluripotent Stem Cells: A Game Changer21:44 Therapeutic Potential of Stem Cells30:44 Organoids and Their Applications in the Laboratory38:47 Future of Stem Cell Research and ApplicationsNotes:Seminal Yamanaka iPSC Creation Paper: https://pubmed.ncbi.nlm.nih.gov/16904174/International Society of Stem Cell Research (ISSCR): https://www.isscr.org/ | — | ||||||
| 11/10/25 | Introducing The ReProgram Podcast | Episode 0In the premier episode of The ReProgram podcast, Dr. George Murphy introduces the concept of reprogramming oneself for resilience against disease and disability. He shares his existential crisis about focusing on disease treatment rather than prevention, leading to a new approach centered on studing dynamic resilience, or our ability to robustly respond to insult and injury. The episode also outlines topics for future discussions, including the history and use of stem cells in regenerative medicine, exceptional longevity and centenarians, and the realities of age reversal.Keywordsreprogramming, resilience, iPSCs, stem cells, disease prevention, dynamic resilience, centenarians, longevity, regenerative medicine, geroscience, age reversalTakeawaysReprogramming oneself can lead to resilience against disease.Focusing on disease prevention is more effective than treatment.Centenarians offer insights into exceptional longevity.Genes and mechanisms drive resilience to disease.Understanding aging is crucial before we can even begin to contemplate age reversal.The podcast explores longevity and geroscience.Office ArtifactOn the desk: Avengers Marvel Legends Full Scale Iron Man Electronic HelmetChapters(00:00:00) Introduction to The ReProgram podcast(00:00:35) The Role of Master Stem Cells in Disease Modeling and Regenerative Medicine(00:01:58) Existential Crisis and a New Approach to Science and Medicine(00:04:22) Dynamic Resilience and Longevity(00:05:16) Future Topics and Explorations | — | ||||||
Showing 20 of 20
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.